German Tech Giant Merck Launches Digital Hub in Singapore to Boost Healthcare and Semiconductor Research
Merck KGaA (ETR: MRK), a leading German technology company, last week inaugurated a digital hub...
Merck
Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...
MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...
Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial
Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...
MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...
C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials
C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...
MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females
Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...
MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...
MSD Advances Four Oncology Candidates to Late-Stage Trials, Including Partnerships with Kelun-Biotech and Orion
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline...
Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential
Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...
FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer
The US Food and Drug Administration (FDA) has accepted under priority review a filing from...
Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program
French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug...
FDA Rejects MSD’s Gefapixant for Chronic Cough Treatment Over Efficacy Concerns
The US Food and Drug Administration (FDA) has declined to approve a filing from Merck,...
MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers
US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership...
European Commission Expands Keytruda Indications for Advanced Cancer Treatments
The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...
FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer
Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...